Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study

被引：0
|
作者：
Ezinwanne Onuoha
Andrew D. Smith
Robert Cannon
Moh’d Khushman
Harrison Kim
机构：
[1] University of Alabama,Department of Biomedical Engineering
[2] University of Alabama,Department of Radiology
[3] University of Alabama,Department of Surgery
[4] University of Alabama,Department of Medicine
来源：
Journal of Gastrointestinal Cancer | 2023年 / 54卷
关键词：
Hepatocellular carcinoma; Perfusion; Atezolizumab; Bevacizumab; Immune therapy; Anti-angiogenic therapy; Therapy response assessment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：776 / 781
页数：5
相关论文
共 50 条
  • [41] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Faiza Ahmed
    Jennifer Onwumeh-Okwundu
    Zeynep Yukselen
    Maria-Kassandra Endaya Coronel
    Madiha Zaidi
    Prathima Guntipalli
    Vamsi Garimella
    Sravya Gudapati
    Marc Darlene Mezidor
    Kim Andrews
    Mohamad Mouchli
    Endrit Shahini
    World Journal of Gastrointestinal Oncology, 2021, 13 (11) : 1813 - 1832
  • [42] Atezolizumab and Bevacizumab in Hepatocellular Carcinoma REPLY
    Finn, Richard S.
    Cheng, Ann-Lii
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07): : 695 - 695
  • [43] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Gong, Hongyu
    Ong, Siew Chin
    Li, Fan
    Weng, Zhiying
    Zhao, Keying
    Jiang, Zhengyou
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [44] Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
    Han, Ji Won
    Jang, Jeong Won
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [45] Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
    Brackenier, Cedric
    Kinget, Lisa
    Cappuyns, Sarah
    Verslype, Chris
    Beuselinck, Benoit
    Dekervel, Jeroen
    CANCERS, 2023, 15 (02)
  • [46] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
    Hoang, H. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
  • [47] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Esmail, Abdullah
    Xu, Jiaqiong
    Burns, Ethan A.
    Abboud, Karen
    Sheikh, Ali
    Umoru, Godsfavour
    Gee, Kelly
    Wiechmann, Catherine
    Zhang, Yuqi
    Abdelrahim, Maen
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [48] Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
    Itoh, Shinji
    Ikeda, Masafumi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022,
  • [49] A case of hepatocellular carcinoma with “pseudoprogression” followed by complete response to atezolizumab plus bevacizumab
    Naoshi Odagiri
    Akihiro Tamori
    Kohei Kotani
    Hiroyuki Motoyama
    Etsushi Kawamura
    Atsushi Hagihara
    Hideki Fujii
    Sawako Uchida‑Kobayashi
    Masaru Enomoto
    Norifumi Kawada
    Clinical Journal of Gastroenterology, 2023, 16 : 392 - 396
  • [50] Preliminary Evaluation of Atezolizumab plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation
    Yang, Zhe
    Sun, Jingqi
    Zhuang, Li
    Mou, Haibo
    Zheng, Shusen
    LIVER TRANSPLANTATION, 2022, 28 (05) : 895 - 896
12345